Caris Life Sciences, Inc.
CAI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $217 | $181 | $121 | $100 |
| % Growth | 19.5% | 50% | 20.9% | – |
| Cost of Goods Sold | $69 | $68 | $64 | $62 |
| Gross Profit | $148 | $114 | $57 | $38 |
| % Margin | 68% | 62.7% | 47.2% | 37.5% |
| R&D Expenses | $22 | $25 | $23 | $25 |
| G&A Expenses | $52 | $64 | $53 | $41 |
| SG&A Expenses | $93 | $107 | $92 | $80 |
| Sales & Mktg Exp. | $41 | $42 | $39 | $39 |
| Other Operating Expenses | $0 | -$36 | $0 | -$134 |
| Operating Expenses | $115 | $96 | $115 | -$29 |
| Operating Income | $33 | $18 | -$58 | $67 |
| % Margin | 15.1% | 9.9% | -47.9% | 67% |
| Other Income/Exp. Net | -$8 | -$90 | -$45 | -$133 |
| Pre-Tax Income | $24 | -$72 | -$103 | -$66 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $24 | -$72 | -$103 | -$66 |
| % Margin | 11.2% | -39.6% | -84.8% | -66.2% |
| EPS | 0.086 | -1.93 | -0.4 | -0.35 |
| % Growth | 104.5% | -382.5% | -14.3% | – |
| EPS Diluted | 0.082 | -1.87 | -0.4 | -0.35 |
| Weighted Avg Shares Out | 282 | 268 | 255 | 255 |
| Weighted Avg Shares Out Dil | 297 | 276 | 255 | 255 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $2 | $1 | $3 |
| Interest Expense | $14 | $19 | $13 | $14 |
| Depreciation & Amortization | $5 | $6 | $7 | $12 |
| EBITDA | $43 | -$46 | -$83 | -$41 |
| % Margin | 19.7% | -25.5% | -68.4% | -40.9% |